SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is trending due to significant developments, including a strategic integration with World Liberty Financial for USD1 payroll and card services, alongside the anticipated launch of its Super App. The community is actively discussing ZBCN's ISO 20022 and MiCA compliance, with many holders expressing strong bullish sentiment, viewing it as an undervalued utility token primed for institutional adoption and substantial long-term growth, despite some market skepticism.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is trending following news that Madryn Asset Management acquired a 91% stake, sparking widespread discussion about potential privatization or delisting to reduce costs. This has fueled significant bullish sentiment, with many anticipating a massive short squeeze due to the extremely low public float, while others express caution regarding potential dilution or the implications of a corporate takeover.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending amidst multiple analyst downgrades and intensified competitive pressure, notably from Apple's new creative software offerings and the broader impact of AI. Community perspectives are sharply divided, with many fearing AI will significantly disrupt Adobe's established business, while others highlight strong fundamentals and view the current dip as a substantial buying opportunity. This reflects a wider market re-evaluation of the software sector's long-term outlook in the face of rapid AI innovation.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending amidst significant volatility, experiencing sharp declines linked to broader ad tech sector weakness and concerns about OpenAI's potential entry into the advertising market. This price action occurred despite multiple recent analyst upgrades reinforcing the company's AI-powered Axon platform and e-commerce expansion. The community remains divided, with many actively buying the dip while others express concerns about overvaluation and potential market manipulation around options activity.

Wishing Well

Wishing Well (WISH CRYPTO) is actively trending as this Solana-based memecoin celebrates hitting a new all-time high and recent listings on prominent crypto platforms. The community is highly engaged, discussing its unique deflationary tokenomics that feature monthly burns matching US inflation, alongside ongoing events and rewards designed to benefit long-term holders.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is actively trending amid community excitement over its innovative smart contract automation, particularly its role as the first on Ethereum's new EIL testnet and recent integrations with Base, Abstract Chain, and Shogun. Discussions are buzzing about increasing holder counts, rising volume, and the impending end of PRQ arbitrage, which many believe will unleash significant price discovery for this potential core infrastructure. Despite lingering skepticism from some, proponents are confident in REACT's long-term utility and growth potential.

Story is a purpose-built layer 1 blockchain designed specifically to onramp intellectual property (IP) to the blockchain and make it programmable.  Story tokenizes any type of IP; whether that’s an idea, an image, a real world asset, a song, an AI model, an NFT or anything in-between. By embedding usage terms, attribution, and royalty agreements directly into the blockchain, Story provides a transparent, decentralized solution for IP management. This enables IP holders to protect their work, collaborate on IP seamlessly, and unlock revenue opportunities in an AI-powered economy.

Story Protocol

Story Protocol ($IP) is trending due to recent on-chain prediction market launches and a privacy upgrade, highlighting its role as a Layer 1 blockchain focused on tokenizing intellectual property for AI and RWA sectors. The community is actively discussing its strong growth potential and drawing comparisons to other tokens with recent parabolic runs, fueled by expectations of further adoption and potential exchange listings. Many investors see $IP as a crucial long-term asset in the evolving digital economy, with significant buzz around its unique utility in programmable IP for the AI era.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is sparking significant community discussion, driven by observations of growing market capitalization, increasing holders, and strong trading volume. Enthusiasts are actively debating its long-term viability against concerns of a potential "rug pull," while a common talking point remains the active search for platforms and methods to acquire the asset.

Decentraland

Decentraland ($MANA) is trending strongly as the community buzzes with speculation around potential partnerships or adoption by major tech players like Apple and Facebook, particularly concerning VR and mobile integration. This fervent discussion signals a collective belief that the Metaverse is poised for a significant resurgence, with many actively promoting MANA as a leading force, directly challenging previous narratives of its demise.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - VR PRF PERPETUAL USD 100 - Ser A

Strive Inc

Strive Inc.'s preferred stock, SATA, is trending due to reaching the $100 threshold, which enables the company to initiate non-dilutive At-The-Market sales. This milestone is generating significant bullish sentiment within the community, as the proceeds are intended to acquire Bitcoin and amplify Strive's digital asset holdings without diluting common shares.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 7.1% - Still a Buy?

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 7.1% - Should You Buy...

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% - Should You Sell?

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 6.5% - Time to Sell...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat reports. One...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5% - Here's Why

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Up 3.5% - Still a Buy...

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.1% Higher - What's Next?

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 7.1% - Here's Why...

Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month High - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month High - Should You Buy...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat...

Foresite Capital Management VI LLC Boosts Position in Corvus Pharmaceuticals, Inc. $CRVS

Foresite Capital Management VI LLC lifted its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 9.5% in the 2nd quarter, according to its most recent disclosure with...

BML Capital Management LLC Buys New Stake in Corvus Pharmaceuticals, Inc. $CRVS

BML Capital Management LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with...

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 7.4% - Still a Buy?

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.4% Higher - What's Next...

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Users are intensely focused on strong EASI reduction rates and a potential "durability signal" from Cohort 4 data, hoping for best-in-class results.

Traders are eagerly awaiting the detailed Cohort 4 clinical trial results for Atopic Dermatitis, which are largely expected to be announced on Tuesday.

Based on potential outstanding data, many users are speculating on significant price increases, with targets ranging from $15 to $100 per share.

Corvus Pharmaceuticals is generating significant buzz as investors eagerly await the pivotal January readout of Cohort 4 data for its oral Atopic Dermatitis therapy, Soquelitinib, building on recent positive T-cell lymphoma results. The community is actively discussing the drug's potential as a best-in-class oral option for the large AD market, with many speculating about upcoming partnerships or a buyout, particularly fueled by a new board member from Novo Nordisk and a notable valuation gap compared to industry peers.

CRVS
Corvus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRVS News

CRVSCorvus Pharmaceuticals Inc